Glucokinase Gene Mutations: Structural and Genotype-Phenotype Analyses in MODY Children from South Italy

Background Maturity onset diabetes of the young type 2 (or GCK MODY) is a genetic form of diabetes mellitus provoked by mutations in the glucokinase gene (GCK). Methodology/Principal Findings We screened the GCK gene by direct sequencing in 30 patients from South Italy with suspected MODY. The mutation-induced structural alterations in the protein were analyzed by molecular modeling. The patients' biochemical, clinical and anamnestic data were obtained. Mutations were detected in 16/30 patients (53%); 9 of the 12 mutations identified were novel (p.Glu70Asp, p.Phe123Leu, p.Asp132Asn, p.His137Asp, p.Gly162Asp, p.Thr168Ala, p.Arg392Ser, p.Glu290X, p.Gln106_Met107delinsLeu) and are in regions involved in structural rearrangements required for catalysis. The prevalence of mutation sites was higher in the small domain (7/12: ∼59%) than in the large (4/12: 33%) domain or in the connection (1/12: 8%) region of the protein. Mild diabetic phenotypes were detected in almost all patients [mean (SD) OGTT = 7.8 mMol/L (1.8)] and mean triglyceride levels were lower in mutated than in unmutated GCK patients (p = 0.04). Conclusions The prevalence of GCK MODY is high in southern Italy, and the GCK small domain is a hot spot for MODY mutations. Both the severity of the GCK mutation and the genetic background seem to play a relevant role in the GCK MODY phenotype. Indeed, a partial genotype-phenotype correlation was identified in related patients (3 pairs of siblings) but not in two unrelated children bearing the same mutation. Thus, the molecular approach allows the physician to confirm the diagnosis and to predict severity of the mutation.

[1]  W. V. van Gunsteren,et al.  An efficient mean solvation force model for use in molecular dynamics simulations of proteins in aqueous solution. , 1996, Journal of molecular biology.

[2]  A. Gloyn Glucokinase (GCK) mutations in hyper‐ and hypoglycemia: Maturity‐onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy , 2003, Human mutation.

[3]  R. Lorini,et al.  High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI , 2001, Diabetologia.

[4]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[5]  M. Veiga-da-Cunha,et al.  Amino Acid Conservation in Animal Glucokinases , 1996, The Journal of Biological Chemistry.

[6]  M. Stoffel,et al.  Human glucokinase gene: isolation, characterization, and identification of two missense mutations linked to early-onset non-insulin-dependent (type 2) diabetes mellitus. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Polak,et al.  An assessment of pancreatic endocrine function and insulin sensitivity in patients with transient neonatal diabetes in remission , 2004, Archives of Disease in Childhood - Fetal and Neonatal Edition.

[8]  C. Wanner,et al.  Are glucokinase mutations associated with low triglycerides? , 2005, Clinical chemistry.

[9]  Shumei S. Guo,et al.  2000 CDC Growth Charts for the United States: methods and development. , 2002, Vital and health statistics. Series 11, Data from the National Health Survey.

[10]  J. D. den Dunnen,et al.  Standardizing mutation nomenclature: Why bother? , 2003, Human mutation.

[11]  T. Frayling,et al.  Insights on pathogenesis of type 2 diabetes from MODY genetics , 2007, Current diabetes reports.

[12]  C. Buettger,et al.  Cell-biological assessment of human glucokinase mutants causing maturity-onset diabetes of the young type 2 (MODY-2) or glucokinase-linked hyperinsulinaemia (GK-HI). , 1999, The Biochemical journal.

[13]  P. Stenson,et al.  The Human Gene Mutation Database (HGMD) and Its Exploitation in the Study of Mutational Mechanisms , 2005, Current protocols in bioinformatics.

[14]  M. White,et al.  Molecular insights into insulin action and secretion , 2002, European journal of clinical investigation.

[15]  H. Fromm,et al.  Regulation of hexokinase I: crystal structure of recombinant human brain hexokinase complexed with glucose and phosphate. , 1998, Journal of molecular biology.

[16]  G I Bell,et al.  Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. , 2001, The New England journal of medicine.

[17]  N. Ben-Tal,et al.  The ConSurf‐HSSP database: The mapping of evolutionary conservation among homologs onto PDB structures , 2004, Proteins.

[18]  D. Lipman,et al.  National Center for Biotechnology Information , 2019, Springer Reference Medizin.

[19]  Teruyuki Nishimura,et al.  Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. , 2004, Structure.

[20]  T. Hansen,et al.  Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young , 2007, Diabetologia.

[21]  A. Sali,et al.  Modeller: generation and refinement of homology-based protein structure models. , 2003, Methods in enzymology.

[22]  Shumei S. Guo,et al.  CDC GROWTH CHARTS FOR THE UNITED STATES: METHODS AND DEVELOPMENT 2000 , 2002 .

[23]  M. Gahr,et al.  Identification of novel GCK and HNF1A/TCF1 mutations and polymorphisms in German families with maturity‐onset diabetes of the young (MODY) , 2005, Human Mutation.

[24]  A. Molven,et al.  Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction , 2006, Nature Genetics.

[25]  O. Horaitis,et al.  Human Genome Variation Society , 2006, Springer Reference Medizin.

[26]  T. Hansen,et al.  Six novel mutations in the GCK gene in MODY patients , 2006, Clinical genetics.

[27]  Sian Ellard,et al.  Mutations in the glucokinase gene of the fetus result in reduced birth weight , 1998, Nature Genetics.

[28]  Lester R Curtin,et al.  Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. , 2002, Pediatrics.

[29]  S. Antonarakis,et al.  Nomenclature for the description of human sequence variations , 2001, Human Genetics.

[30]  C. de Beaufort,et al.  From Clinicogenetic Studies of Maturity-Onset Diabetes of the Young to Unraveling Complex Mechanisms of Glucokinase Regulation , 2006, Diabetes.

[31]  P. Iynedjian Mammalian glucokinase and its gene. , 1993, The Biochemical journal.

[32]  A. Franzese,et al.  MODY 2 presenting as neonatal hyperglycaemia: a need to reshape the definition of “neonatal diabetes”? , 2000, Diabetologia.

[33]  E. Blázquez,et al.  Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity , 2007, Diabetologia.

[34]  P. Froguel,et al.  Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families , 1997, Diabetologia.

[35]  Ncbi National Center for Biotechnology Information , 2008 .

[36]  S. Zucchini,et al.  Identification of eight novel glucokinase mutations in Italian children with maturity‐onset diabetes of the young , 2003, Human mutation.

[37]  Stephen P. Miller,et al.  Characterization of glucokinase mutations associated with maturity-onset diabetes of the young type 2 (MODY-2): different glucokinase defects lead to a common phenotype. , 1999, Diabetes.